| Drug Name |
Roflumilast |
| Drug ID |
BADD_D01962 |
| Description |
Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor. Due to its selective inhibition of the PDE4 isoenzyme in lung cells, roflumilast is indicated for the management of chronic obstrtuctive pulmonary disease (COPD) exacerbations. Treatment with Roflumilast is associated with an increase in psychiatric adverse reactions, including suicide and suicidal attempts. |
| Indications and Usage |
Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm. |
| Marketing Status |
Prescription |
| ATC Code |
R03DX07 |
| DrugBank ID |
DB01656
|
| KEGG ID |
D05744
|
| MeSH ID |
C424423
|
| PubChem ID |
449193
|
| TTD Drug ID |
D0R4UW
|
| NDC Product Code |
43265-7463; 47234-0088; 64552-4053; 54245-7016; 65977-0111; 82245-0118; 43265-7462; 0310-0088; 0310-0095; 47234-0095; 14501-0078; 65015-850; 59651-222 |
| Synonyms |
Roflumilast | 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide | daliresp |
